126 related articles for article (PubMed ID: 31611061)
1. Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis.
Juan C
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Dec; 37(10):623-625. PubMed ID: 31611061
[No Abstract] [Full Text] [Related]
2. Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study.
Valero A; Isla A; Rodríguez-Gascón A; Canut A; Ángeles Solinís M
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Dec; 37(10):626-633. PubMed ID: 31005313
[TBL] [Abstract][Full Text] [Related]
3. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
Fish DN; Kiser TH
Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
[TBL] [Abstract][Full Text] [Related]
4. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Miyazaki S
J Infect Chemother; 2004 Apr; 10(2):135. PubMed ID: 15160313
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo.
Hengzhuang W; Høiby N; Ciofu O
Methods Mol Biol; 2014; 1147():239-54. PubMed ID: 24664838
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa.
Cardozo C; Rico V; Agüero D; Soriano A
Rev Esp Quimioter; 2019 Sep; 32 Suppl 2(Suppl 2):32-34. PubMed ID: 31475807
[TBL] [Abstract][Full Text] [Related]
7. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
8. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
[TBL] [Abstract][Full Text] [Related]
11. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
[TBL] [Abstract][Full Text] [Related]
12. Report of a KPC-producing Pseudomonas aeruginosa isolate in Canada.
Walkty A; Alexander DC; Karlowsky JA; Nichol K; Embil J
J Antimicrob Chemother; 2019 Jun; 74(6):1748-1749. PubMed ID: 30783655
[No Abstract] [Full Text] [Related]
13. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
14. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO
Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
[No Abstract] [Full Text] [Related]
15. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
Khan DD; Friberg LE; Nielsen EI
J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
Plant AJ; Dunn A; Porter RJ
Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
[No Abstract] [Full Text] [Related]
17. [Antibiotic resistance of some Pseudomonas aeruginosa isolates].
Matinca D; Vancea D; Boboş C; Serban O
Bacteriol Virusol Parazitol Epidemiol; 2003; 48(2-3):157-61. PubMed ID: 15341333
[No Abstract] [Full Text] [Related]
18. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.
Zavascki AP; Carvalhaes CG; Picão RC; Gales AC
Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903
[TBL] [Abstract][Full Text] [Related]
19. [Drug sensitivity of Pseudomonas aeruginosa isolated from burn wounds during 1985/1986 and its serologic types].
Ziółkowski G; Dudzińska G; Sakiel S
Pol Tyg Lek; 1988 Dec; 43(49):1596-8. PubMed ID: 3151376
[No Abstract] [Full Text] [Related]
20. Rapid Polymyxin/Pseudomonas NP test for rapid detection of polymyxin susceptibility/resistance in Pseudomonas aeruginosa.
Sadek M; Tinguely C; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1657-1662. PubMed ID: 32318967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
